Access Bio, Inc. (KOSDAQ:950130)
South Korea · Delayed Price · Currency is KRW 3,210.00
-90.00 (-2.73%)
At close: Feb 27, 2026
Access Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Other Revenue | - | - | - | - | 0 | - |
Revenue | 54,666 | 112,463 | 348,643 | 1,033,863 | 505,112 | 121,797 |
Revenue Growth (YoY) | -54.47% | -67.74% | -66.28% | 104.68% | 314.71% | 182.86% |
Cost of Revenue | 48,832 | 59,197 | 178,765 | 214,488 | 109,147 | 31,164 |
Gross Profit | 5,834 | 53,266 | 169,878 | 819,375 | 395,965 | 90,634 |
Selling, General & Admin | 33,329 | 44,819 | 197,435 | 343,560 | 55,945 | 14,485 |
Research & Development | 8,366 | 10,837 | 16,081 | 7,316 | 4,894 | 4,006 |
Amortization of Goodwill & Intangibles | 202.96 | 228.15 | 248.5 | 246.23 | 230.14 | 394.98 |
Other Operating Expenses | 113.95 | 103.17 | 133.52 | 93.09 | 82.15 | 76.18 |
Operating Expenses | 51,498 | 65,867 | 147,956 | 351,137 | 136,296 | 24,097 |
Operating Income | -45,665 | -12,602 | 21,922 | 468,238 | 259,669 | 66,536 |
Interest Expense | -3,019 | -3,470 | -3,711 | -6,233 | -3,350 | -1,867 |
Interest & Investment Income | 13,449 | 14,593 | 14,433 | 5,710 | 211.98 | 126.88 |
Currency Exchange Gain (Loss) | -869.92 | -1,403 | -198.98 | -169.12 | -546.48 | 721.11 |
Other Non Operating Income (Expenses) | 1,203 | 8,837 | -41,370 | -7,750 | 757.1 | -61.01 |
EBT Excluding Unusual Items | -34,902 | 5,954 | -8,926 | 459,796 | 256,742 | 65,456 |
Gain (Loss) on Sale of Investments | -898.23 | -4,707 | 1,080 | 12.79 | - | - |
Gain (Loss) on Sale of Assets | -10.98 | -3.16 | -0.89 | -41.39 | 18.46 | -98.89 |
Asset Writedown | -1,389 | -1,389 | 1,967 | -1.1 | - | -2,896 |
Other Unusual Items | - | - | - | 3,929 | - | 17.43 |
Pretax Income | -37,200 | -143.86 | -5,879 | 463,696 | 256,760 | 62,479 |
Income Tax Expense | -8,465 | 936 | -580.48 | 113,951 | 66,683 | 14,667 |
Earnings From Continuing Operations | -28,735 | -1,080 | -5,299 | 349,746 | 190,077 | 47,812 |
Minority Interest in Earnings | 692.63 | 732.29 | 2,126 | -3,075 | -387.22 | 460.3 |
Net Income | -28,042 | -347.58 | -3,173 | 346,670 | 189,690 | 48,272 |
Net Income to Common | -28,042 | -347.58 | -3,173 | 346,670 | 189,690 | 48,272 |
Net Income Growth | - | - | - | 82.76% | 292.96% | - |
Shares Outstanding (Basic) | 37 | 34 | 34 | 34 | 36 | 34 |
Shares Outstanding (Diluted) | 37 | 34 | 34 | 38 | 37 | 35 |
Shares Change (YoY) | 12.73% | 1.38% | -10.73% | 1.46% | 7.75% | 21.66% |
EPS (Basic) | -767.87 | -10.15 | -93.91 | 10050.42 | 5328.07 | 1432.85 |
EPS (Diluted) | -767.87 | -10.15 | -93.91 | 9212.00 | 5127.00 | 1392.00 |
EPS Growth | - | - | - | 79.68% | 268.32% | - |
Free Cash Flow | -32,431 | 17,853 | -122,498 | 350,444 | 129,398 | 25,256 |
Free Cash Flow Per Share | -888.07 | 521.24 | -3625.74 | 9259.21 | 3468.64 | 729.46 |
Gross Margin | 10.67% | 47.36% | 48.73% | 79.25% | 78.39% | 74.41% |
Operating Margin | -83.53% | -11.21% | 6.29% | 45.29% | 51.41% | 54.63% |
Profit Margin | -51.30% | -0.31% | -0.91% | 33.53% | 37.55% | 39.63% |
Free Cash Flow Margin | -59.33% | 15.88% | -35.14% | 33.90% | 25.62% | 20.74% |
EBITDA | -24,919 | 7,476 | 37,882 | 479,065 | 265,733 | 69,950 |
EBITDA Margin | -45.58% | 6.65% | 10.87% | 46.34% | 52.61% | 57.43% |
D&A For EBITDA | 20,746 | 20,078 | 15,960 | 10,826 | 6,064 | 3,414 |
EBIT | -45,665 | -12,602 | 21,922 | 468,238 | 259,669 | 66,536 |
EBIT Margin | -83.53% | -11.21% | 6.29% | 45.29% | 51.41% | 54.63% |
Effective Tax Rate | - | - | - | 24.57% | 25.97% | 23.47% |
Advertising Expenses | - | 722.23 | 678.33 | 1,523 | 1,113 | 1,025 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.